Furthermore, pediatric neuroblastoma patients with age at diagnosis < 18 months and with lower E2F3 expression levels had the best clinical event free survival and overall survival than other sub-groups in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets (Fig. 6b and supplementary Fig. 3b). This evidence concerns the gene E2F3 and neuroblastoma.